Adverum Biotechnologies (ADVM) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends up on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Adverum Biotechnologies Reports Recent Business Progress and Fourth Quarter 2019 Financial Results
March 12, 2020 4:01 PM EDT-- Cohort 3 dosing complete and cohort 4 screening underway in OPTIC Phase 1 trial of ADVM-022 in wet AMD --Â -- New OPTIC data to be presented in May 2020 ---- Data from all four cohorts of OPTIC planned in 2020 --
-- Company to host conference call today at 1:30 pm PT / 4:30 pm ET --
REDWOOD CITY, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial... More
